Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 3.17
BIIB's Cash to Debt is ranked higher than
63% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. BIIB: 3.17 )
BIIB' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 3.17

Equity to Asset 0.76
BIIB's Equity to Asset is ranked higher than
79% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BIIB: 0.76 )
BIIB' s 10-Year Equity to Asset Range
Min: 0.54   Max: 0.85
Current: 0.76

0.54
0.85
Interest Coverage 78.86
BIIB's Interest Coverage is ranked higher than
55% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 78.86 )
BIIB' s 10-Year Interest Coverage Range
Min: 2.3   Max: 9999.99
Current: 78.86

2.3
9999.99
F-Score: 8
Z-Score: 17.60
M-Score: -2.38
WACC vs ROIC
8.00%
30.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 38.44
BIIB's Operating margin (%) is ranked higher than
97% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. BIIB: 38.44 )
BIIB' s 10-Year Operating margin (%) Range
Min: -128.05   Max: 52.91
Current: 38.44

-128.05
52.91
Net-margin (%) 27.79
BIIB's Net-margin (%) is ranked higher than
95% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. BIIB: 27.79 )
BIIB' s 10-Year Net-margin (%) Range
Min: -128.85   Max: 36.64
Current: 27.79

-128.85
36.64
ROE (%) 27.34
BIIB's ROE (%) is ranked higher than
97% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. BIIB: 27.34 )
BIIB' s 10-Year ROE (%) Range
Min: -21.44   Max: 31.98
Current: 27.34

-21.44
31.98
ROA (%) 20.24
BIIB's ROA (%) is ranked higher than
97% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. BIIB: 20.24 )
BIIB' s 10-Year ROA (%) Range
Min: -15.14   Max: 24.62
Current: 20.24

-15.14
24.62
ROC (Joel Greenblatt) (%) 155.44
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. BIIB: 155.44 )
BIIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.79   Max: 211.79
Current: 155.44

-62.79
211.79
Revenue Growth (3Y)(%) 16.30
BIIB's Revenue Growth (3Y)(%) is ranked higher than
88% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. BIIB: 16.30 )
BIIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -13.9   Max: 84.7
Current: 16.3

-13.9
84.7
EBITDA Growth (3Y)(%) 26.20
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BIIB: 26.20 )
BIIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.4   Max: 86
Current: 26.2

-16.4
86
EPS Growth (3Y)(%) 25.60
BIIB's EPS Growth (3Y)(%) is ranked higher than
91% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BIIB: 25.60 )
BIIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -66   Max: 205.2
Current: 25.6

-66
205.2
» BIIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BIIB Guru Trades in Q1 2014

Caxton Associates 10,000 sh (New)
Andreas Halvorsen 388,900 sh (New)
Ron Baron 6,089 sh (New)
John Burbank 783 sh (New)
George Soros 7,500 sh (New)
Ken Heebner 116,000 sh (New)
Joel Greenblatt 3,931 sh (New)
Ken Fisher 18,266 sh (+796.27%)
Jeremy Grantham 476,999 sh (+250.14%)
Paul Tudor Jones 3,299 sh (+86.7%)
Frank Sands 4,873,017 sh (+2.5%)
Bill Frels 1,125 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 8,493 sh (-0.46%)
Steven Cohen 258,862 sh (-0.78%)
PRIMECAP Management 17,502,106 sh (-1.55%)
Mario Gabelli 3,585 sh (-3.37%)
RS Investment Management 17,671 sh (-9.28%)
Pioneer Investments 1,251 sh (-15.19%)
Vanguard Health Care Fund 599,400 sh (-32.19%)
» More
Q2 2014

BIIB Guru Trades in Q2 2014

Stanley Druckenmiller 103,800 sh (New)
Louis Moore Bacon 32,500 sh (New)
Jim Simons 129,261 sh (New)
Ken Fisher 88,885 sh (+386.61%)
Jeremy Grantham 857,799 sh (+79.83%)
Ron Baron 8,632 sh (+41.76%)
Mario Gabelli 4,175 sh (+16.46%)
Frank Sands 4,891,463 sh (+0.38%)
Steven Cohen 7,600 sh (unchged)
Bill Frels 1,125 sh (unchged)
Murray Stahl 8,493 sh (unchged)
Caxton Associates Sold Out
Andreas Halvorsen Sold Out
George Soros Sold Out
Ken Heebner Sold Out
Joel Greenblatt Sold Out
John Burbank Sold Out
PRIMECAP Management 17,258,311 sh (-1.39%)
Pioneer Investments 1,232 sh (-1.52%)
Vanguard Health Care Fund 559,700 sh (-6.62%)
RS Investment Management 16,250 sh (-8.04%)
Paul Tudor Jones 899 sh (-72.75%)
» More
Q3 2014

BIIB Guru Trades in Q3 2014

Ken Heebner 80,000 sh (New)
Joel Greenblatt 31,391 sh (New)
Ray Dalio 1,646 sh (New)
Paul Tudor Jones 3,061 sh (+240.49%)
RS Investment Management 20,205 sh (+24.34%)
Mario Gabelli 4,635 sh (+11.02%)
Bill Frels 1,170 sh (+4%)
Frank Sands 4,952,096 sh (+1.24%)
Stanley Druckenmiller 103,800 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Ron Baron 8,613 sh (-0.22%)
PRIMECAP Management 17,216,631 sh (-0.24%)
Murray Stahl 8,468 sh (-0.29%)
Jeremy Grantham 800,301 sh (-6.7%)
Ken Fisher 78,457 sh (-11.73%)
Pioneer Investments 1,069 sh (-13.23%)
Jim Simons 92,661 sh (-28.31%)
Vanguard Health Care Fund 233,600 sh (-58.26%)
» More
Q4 2014

BIIB Guru Trades in Q4 2014

Ken Fisher 79,254 sh (+1.02%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Heebner 2014-09-30 New Buy0.75%$299.29 - $346.3 $ 353.257%80000
Vanguard Health Care Fund 2014-09-30 Reduce -58.26%0.27%$299.29 - $346.3 $ 353.257%233600
Joel Greenblatt 2014-09-30 New Buy0.1%$299.29 - $346.3 $ 353.257%31391
Ray Dalio 2014-09-30 New Buy$299.29 - $346.3 $ 353.257%1646
Ken Heebner 2014-06-30 Sold Out 0.95%$274 - $320.13 $ 353.2518%0
Andreas Halvorsen 2014-06-30 Sold Out 0.5%$274 - $320.13 $ 353.2518%0
Ken Fisher 2014-06-30 Add 386.61%0.05%$274 - $320.13 $ 353.2518%88885
Joel Greenblatt 2014-06-30 Sold Out 0.02%$274 - $320.13 $ 353.2518%0
George Soros 2014-06-30 Sold Out 0.02%$274 - $320.13 $ 353.2518%0
John Burbank 2014-06-30 Sold Out 0.01%$274 - $320.13 $ 353.2518%0
Ron Baron 2014-06-30 Add 41.76%$274 - $320.13 $ 353.2518%8632
Ken Heebner 2014-03-31 New Buy0.95%$273.518 - $351.94 $ 353.2512%116000
Andreas Halvorsen 2014-03-31 New Buy0.5%$273.518 - $351.94 $ 353.2512%388900
Vanguard Health Care Fund 2014-03-31 Reduce -32.19%0.24%$273.518 - $351.94 $ 353.2512%599400
Ray Dalio 2014-03-31 Sold Out 0.04%$273.518 - $351.94 $ 353.2512%0
George Soros 2014-03-31 New Buy0.02%$273.518 - $351.94 $ 353.2512%7500
Joel Greenblatt 2014-03-31 New Buy0.02%$273.518 - $351.94 $ 353.2512%3931
John Burbank 2014-03-31 New Buy0.01%$273.518 - $351.94 $ 353.2512%783
Ron Baron 2014-03-31 New Buy0.01%$273.518 - $351.94 $ 353.2512%6089
Ken Fisher 2014-03-31 Add 796.27%0.01%$273.518 - $351.94 $ 353.2512%18266
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Biogen Idec Inc

Ken Fisher's Top Increases of the Second Quarter
CEO and CIO of Fisher Investments and regular Forbes contributor, Ken Fisher, had a pretty busy second quarter. Fisher purchased a total of 50 new stocks. His second quarter portfolio holds 558 stocks and is valued at over $47.56 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings during the second quarter. Read more...
Ken Fisher's Top Increases of the First Quarter
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy first quarter. Fisher purchased a total of 57 new stocks. His first quarter portfolio holds 541 stocks and is valued at over $44.34 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.80
BIIB's P/E(ttm) is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 32.80 )
BIIB' s 10-Year P/E(ttm) Range
Min: 11.74   Max: 120.59
Current: 32.8

11.74
120.59
Forward P/E 19.38
BIIB's Forward P/E is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 19.38 )
N/A
PE(NRI) 32.90
BIIB's PE(NRI) is ranked higher than
94% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 32.90 )
BIIB' s 10-Year PE(NRI) Range
Min: 11.73   Max: 120.59
Current: 32.9

11.73
120.59
P/B 7.90
BIIB's P/B is ranked higher than
69% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. BIIB: 7.90 )
BIIB' s 10-Year P/B Range
Min: 1.86   Max: 9.52
Current: 7.9

1.86
9.52
P/S 9.10
BIIB's P/S is ranked higher than
83% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. BIIB: 9.10 )
BIIB' s 10-Year P/S Range
Min: 2.8   Max: 20.67
Current: 9.1

2.8
20.67
PFCF 31.50
BIIB's PFCF is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 31.50 )
BIIB' s 10-Year PFCF Range
Min: 7.42   Max: 34.82
Current: 31.5

7.42
34.82
POCF 28.67
BIIB's POCF is ranked higher than
93% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 28.67 )
BIIB' s 10-Year POCF Range
Min: 5.72   Max: 35.24
Current: 28.67

5.72
35.24
EV-to-EBIT 23.30
BIIB's EV-to-EBIT is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 23.30 )
BIIB' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 79.3
Current: 23.3

8.3
79.3
PEG 1.64
BIIB's PEG is ranked higher than
98% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 1.64 )
BIIB' s 10-Year PEG Range
Min: 0.84   Max: 2.55
Current: 1.64

0.84
2.55
Shiller P/E 57.30
BIIB's Shiller P/E is ranked higher than
96% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 57.30 )
BIIB' s 10-Year Shiller P/E Range
Min: 30.31   Max: 78.46
Current: 57.3

30.31
78.46
Current Ratio 2.25
BIIB's Current Ratio is ranked higher than
61% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. BIIB: 2.25 )
BIIB' s 10-Year Current Ratio Range
Min: 1.74   Max: 17.39
Current: 2.25

1.74
17.39
Quick Ratio 1.86
BIIB's Quick Ratio is ranked higher than
61% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BIIB: 1.86 )
BIIB' s 10-Year Quick Ratio Range
Min: 1.34   Max: 16.79
Current: 1.86

1.34
16.79
Days Inventory 220.18
BIIB's Days Inventory is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 220.18 )
BIIB' s 10-Year Days Inventory Range
Min: 69.41   Max: 10720.03
Current: 220.18

69.41
10720.03
Days Sales Outstanding 44.12
BIIB's Days Sales Outstanding is ranked higher than
88% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. BIIB: 44.12 )
BIIB' s 10-Year Days Sales Outstanding Range
Min: 4.44   Max: 106.69
Current: 44.12

4.44
106.69

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 17.50
BIIB's Price/Tangible Book is ranked higher than
66% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. BIIB: 17.50 )
BIIB' s 10-Year Price/Tangible Book Range
Min: 0.38   Max: 48.16
Current: 17.5

0.38
48.16
Price/DCF (Projected) 3.40
BIIB's Price/DCF (Projected) is ranked higher than
95% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 3.40 )
BIIB' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 25.99
Current: 3.4

0.65
25.99
Price/Median PS Value 1.60
BIIB's Price/Median PS Value is ranked higher than
77% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. BIIB: 1.60 )
BIIB' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 6.26
Current: 1.6

0.07
6.26
Price/Peter Lynch Fair Value 1.50
BIIB's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 1.50 )
BIIB' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.44   Max: 20.5
Current: 1.5

0.44
20.5
Price/Graham Number 5.10
BIIB's Price/Graham Number is ranked higher than
91% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BIIB: 5.10 )
BIIB' s 10-Year Price/Graham Number Range
Min: 0.43   Max: 21.27
Current: 5.1

0.43
21.27
Earnings Yield (Greenblatt) 4.30
BIIB's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. BIIB: 4.30 )
BIIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 12
Current: 4.3

1.3
12
Forward Rate of Return (Yacktman) 24.03
BIIB's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 14.57 vs. BIIB: 24.03 )
BIIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.7   Max: 33.5
Current: 24.03

2.7
33.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, CELG, CMXHY » details
Traded in other countries:IDP.Germany, BIIB.Mexico, BIIB.Switzerland,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company focused. It discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for BIIB

Headlines

Articles On GuruFocus.com
Google Joins Biogen In The Fight Against Multiple Sclerosis Jan 29 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
Biogen’s Alzheimer’s Drug Moves to Phase III Dec 03 2014 
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 

More From Our Partners
Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Jan 27 2015 - ZACKS

More From Other Websites
Biogen, Alexion Earnings Top Views, Shares Jump Jan 29 2015
Biogen Idec to add 100 jobs in RTP Jan 29 2015
Biogen's Profit Nearly Doubles Jan 29 2015
Biogen tops 4Q profit forecasts Jan 29 2015
Biogen tops 4Q profit forecasts Jan 29 2015
Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Jan 29 2015
Biogen forecasts 2015 earnings well ahead of Street view Jan 29 2015
Biogen shares jump after company reports earnings Jan 29 2015
Biogen Idec Inc Earnings Call scheduled for 4:30 pm ET today Jan 29 2015
BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 29 2015
Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Jan 29 2015
Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Jan 29 2015
Alexion Beats Q4 Estimates, Appoints New CEO Jan 29 2015
Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity' Jan 29 2015
Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog Jan 29 2015
Q4 2014 Biogen Idec Inc Earnings Release - After Market Close Jan 29 2015
5:00 am Biogen Idec, Fondazione Telethon and Ospedale San Raffaele announce global collaboration to... Jan 29 2015
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop... Jan 29 2015
Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop... Jan 29 2015
NFL Hall of Famer Earl Campbell And Son Tyler Campbell Pair Up With Biogen Idec To Celebrate The... Jan 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK